crossing96/oncoscreening huggingface dataset:
[A Case of Sigmoid Colon Cancer with Bladder Invasion Successfully Treated with Chemotherapy with mFOLFOX6+Cetuximab].	A 70' woman presented to our hospital complaining of a weight loss and loss of appetite. She was diagnosed with advanced sigmoid colon cancer by colonoscopy, and CT scan showed that the tumor had invaded the bladder and left ovary, and showed enlarged para-aortic lymph nodes. The tumor was large, and it was determined that a total cystectomy was necessary for radical resection, it was decided to perform pre-operative chemotherapy. Because RAS gene has no mutation, the regimen chose mFOLFOX6, in addition to cetuximab. Although Grade 3 neutropenia was observed, there was no appearance of adverse events that were intolerant, and 6 courses were performed. The treatment resulted in a marked reduction of the tumor. An open sigmoid colon resection with bladder wall and left ovarian cyst were performed. Even after the operation, the course was good, and it was discharged from the hospital lightly on the 10th day after the operation. The histopathological diagnosis was moderately differentiated adenocarcinoma, ypT4b(bladder left ovary), ypN0, M0, ypStage Ⅱc, all with negative surgical margins. She remained recurrence-free for 6 months of postoperative follow up. Cetuximab combination regimen was considered to be an effective option.	bladder
Urinary diversion and quality of life: A six-year follow-up study of bladder cancer surgery.	OBJECTIVES: To evaluate health-related quality of life (HRQOL) six years post-radical cystectomy in patients with muscle-invasive bladder cancer, comparing orthotopic ileal neobladder (ONB) and ileal conduit (IC). Therefore, the study aims to analyze the under-investigated long-term impact of standard bladder cancer treatments on HRQOL and provide insights into the HRQOL differences associated with these two common urinary diversion methods. PATIENTS AND METHODS: This prospective study included 39 patients with urothelial carcinoma treated with ONB or IC at our center between 03/2013 and 01/2023. Patients with variant histology, metastasis, neoadjuvant chemotherapy, or benign indications for cystectomy were excluded. HRQOL was assessed using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire preoperatively, at four and six years postoperatively. Statistical analyses included Chi-square tests, T-tests, and logistic regression models. RESULTS: Of the patients, 64% (25/39) underwent ONB, and 76.9% (30/39) were male, with an average age of 69 years. No significant differences in overall good HRQOL (GHS > 70) were observed between ONB and IC at six years (IC: 60 ± 22; ONB: 69 ± 23, p = 0.2). Patients with IC reported higher insomnia at both follow-ups (4 years: p = 0.01; 6 years: p = 0.03). Emotional function remained stable in ONB patients but declined in IC patients from the fourth to sixth years (p = 0.04). CONCLUSION: Long-term HRQOL did not significantly differ between ONB and IC up to six years post-radical cystectomy. Both urinary diversion methods can be offered to patients, with tailored discussions in terms of HRQOL.	bladder
Urine exosomal lncRNAs as novel biomarkers for early diagnosis of bladder cancer based on microarray differential expression profiling.	PurposeWe aimed to exploit a urine exosomal long non-coding RNAs (lncRNAs) fingerprint to facilitate the early diagnosis of bladder cancer.MethodsMicroarray differential expression profiling of lncRNAs was for the first time employed in urine exosomes from 10 non-muscle-invasive bladder cancer (NMIBC) patients and 10 healthy controls to screen out candidate exosomal lncRNA biomarkers, which were then verified by quantitative real-time polymerase chain reaction in three independent phases including bladder cancer cells, culture fluid and 200 NMIBC participants. Logistic regression was performed to construct a diagnostic model-the diagnostic potency of which was assessed.ResultsThe profile of three exosome-derived lncRNAs (CCDC148-AS1, XLOC_006419, and RP5-1148A21.3) was screened and further verified to be notably over-expressed in NMIBC patients and bladder cancer cell lines, and exhibited area under the receiver-operating characteristic curve values of 0.873, 0.825, and 0.834, respectively, in training, validation, and double-blind validation phases. The profile was superior to urinary cytology in discriminating NMIBC from healthy controls (P < 0.0001). A significant correlation existed between a higher level of CCDC148-AS1 and a higher tumor grade (P < 0.001), and up-regulated CCDC148-AS1 as well as XLOC_006419 were statistically related with tumor node metastasis stage (P = 0.004 and P = 0.031, respectively). These three identified lncRNAs were confirmed to originate from bladder cancer cells and be packaged within exosomes, thus staying sufficiently stable in urine.ConclusionsTumor-originated urine exosomal lncRNAs, as fingerprint in NMIBC, exhibited satisfying clinical significance in early diagnosis of bladder cancer.	bladder
pH-Responsive Triplex DNA Nanoswitches: Surface Plasmon Resonance Platform for Bladder Cancer-Associated microRNAs.	Bladder cancer (BC) has a high recurrence rate, necessitating frequent monitoring. We herein present an innovative method for detecting BC-related miR-183 and miR-155 microRNAs using pH-responsive triplex DNA nanoswitches (TDNs). This approach employs a stepwise surface plasmon resonance biosensing platform (TDNs-SPR assay) to detect these two miRNAs sequentially. The platform involves the assembly of two triplex pH-responsive probes, switch A (SA) and switch B (SB), on an SPR sensing interface by anchoring the probes to the surface through SA/miR-183 and SB/miR-155 binding to the S9.6 antibody-modified surface. The probes are functionalized with streptavidin-Au nanoparticles/biotinylated strands, which act as reporter units for the presence of the respective miRNAs on the sensing interface. The pH-induced displacement of reporter units triggers stepwise SPR reflectivity changes: at pH 5.0 for sensing miR-183 and at pH 8.3 for sensing miR-155. The reflectivity changes relate quantitatively to the concentrations of miRNAs. This sensing platform enables the detection of two miRNAs with detection limits as low as 0.57 pM for miR-183 and 0.83 pM for miR-155, highlighting its powerful utility for precise biomarker analysis. Moreover, this platform distinguishes BC patients from healthy individuals in urine samples. The method offers a versatile, noninvasive method for detecting any two miRNAs associated with other diseases.	bladder
Relationship between intraoperative intestinal cultures and postoperative urinary infection in radical cystectomy with ileal diversion patients.	INTRODUCTION: Radical cystectomy (RC) is a preferred treatment for muscle-invasive bladder cancer (T2-T4) and certain non-muscle-invasive tumors. Post-cystectomy, urinary diversions often utilize intestinal segments, which are prone to complications, notably urinary tract infections (UTIs). OBJECTIVE: To estimate the association between intraoperative cultures of the isolated intestinal loop and urine cultures during UTI episodes in RC patients with urinary diversion. Additionally, to compare urinary cultures from catheters at discharge with UTI cultures and calculate UTI prevalence and readmission rates within three months postoperatively. MATERIALS AND METHODS: This prospective, observational cohort study included patients who underwent RC with ileal segment diversion our center between April 2021 and January 2024. Intraoperative cultures were obtained by washing the isolated ileal loop, and urine cultures were taken during postoperative UTI episodes. Patients were followed for 90 days post-surgery, and new cultures were performed if UTI symptoms appeared. RESULTS: Among 118 cystectomies, 82 patients were included, with a mean age of 67.8 years. UTI prevalence within the first three months was 43.9%. The kappa concordance index for bacteria between intraoperative and UTI cultures was 0.033 (poor), and for cultures from discharge catheters and UTI episodes, it was 0.251 (fair). UTI readmission rate was 28.9%, with no significant predictors identified. CONCLUSION: There is no significant association between germs in intraoperative intestinal cultures or discharge catheters and those in UTI cultures in RC patients with urinary diversion. The three-month UTI prevalence is 43.9%, with a 28.9% readmission rate. Continuous epidemiological surveillance is recommended for appropriate antibiotic therapy.	bladder
Cell-free Tumor DNA: a Promising Technology for Diagnosis, Surveillance and Therapeutic Decision in Urothelial Carcinoma of the Bladder.	PURPOSE OF REVIEW: This narrative review aims to discuss the latest evidence for cell-free tumor DNA (ctDNA) use in bladder cancer, future perspectives and challenges in implementing this technology in clinical practice. RECENT FINDINGS: Recent papers describe promising findings regarding ctDNA analysis in blood samples and in urine of bladder cancer patients. This biomarker can be used as a diagnostic tool, in prognostic evaluation and as additional data for treatment indication and surveillance.	bladder
Socioeconomic disparities in survival of patients with non-muscle invasive urothelial carcinoma.	PURPOSE: Limited data are available on the impact of socioeconomic disparities on the survival of patients with non-muscle invasive urothelial carcinoma (NMIBC). METHODS: We analyzed the Surveillance, Epidemiology, and End Results database to review the effects of sex, race, location, and socioeconomic factors on the survival of patients with NMIBC. We calculated 5-year overall survival (OS) and cancer-specific survival (CSS) using the log-rank test. The impact of socioeconomic factors on OS and CSS was analyzed using the Cox proportional hazards model adjusted for clinical characteristics. Hazard ratios (HR) and survival rates were reported with 95% confidence intervals (CI). RESULTS: Analysis of 3831 patients showed that older age was associated with worse OS (HR 1.08 [1.08-1.09]) and CSS (HR 1.05 [1.04-1.06]). Women and men had similar OS (HR 0.91 [0.82-1.01]) and CSS (HR 1.12 [0.95-1.32]). Black patients had worse OS (HR 1.33 [1.08-1.62] and CSS [HR 1.54 [1.13-2.05]) than their White counterparts. Patients with an annual household income below $40,000 had worse outcomes compared to those with income above $70,000 for both OS (HR 1.79 [1.37-2.33]) and CSS (HR 1.924 [1.26-2.89]). CONCLUSIONS: There were no gender differences in survival outcomes of NMIBC. Older age, Black, American Indian/Alaskan Native, and patients with a household income below $40,000 appear to have worse survival. However, the area of residence did not seem to affect patient survival.	bladder
Efficacy of curative radiotherapy for the treatment of elderly patients with muscle-invasive bladder cancer: a systematic review.	INTRODUCTION: In recent years, a chemoradiotherapy has been developed as a radical treatment for stage II-III muscle-invasive bladder cancer (MIBC) that can preserve the bladder for patients who cannot tolerate radical cystectomy (RC) or who do not wish to undergo RC. However, most of the studies were conducted on younger patients with MIBC, and it is not clear if it is effective for elderly patients with MIBC. In this study, we reviewed the effects and adverse events after radical radiotherapy in elderly patients with MIBC to determine if radiotherapy has been/can be equally recommended for younger patients with MIBC. METHODS: We extracted full research reports in English comparing treatment results between different age groups and reports targeting elderly patients with MIBC. A keyword search of the PubMed database was conducted in the decade ending on December 8, 2021. Studies reporting post-treatment overall survival (OS), relapse-free/progression-free/disease-free survival (RFS/PFS/DFS), disease-specific/cancer-specific survival (DSS/CSS), and complete response (CR) rate, adverse events (AEs), and quality of life (QOL) in elderly patients with MIBC were searched. Thirty-nine full articles, including those with comparisons by age group or treatments for elderly patients, were retrieved. RESULTS: OS was significant or tended to be poor in elderly patients. There were no differences in PFS and CSS between younger and elderly patients. No differences in the rates of grade 3 morbidities between younger and elderly patients were also observed. CONCLUSION: The lack of a difference in PFS/CSS and toxicities between elderly and younger MIBC patients indicated that curative chemoradiotherapy is effective for not only younger but also elderly patients. With advances in treatment, further prospective studies are needed to optimize the management of MIBC in elderly patients.	bladder
SIRI as a biomarker for bladder neoplasm: Utilizing decision curve analysis to evaluate clinical net benefit.	PURPOSE: This analysis aimed to evaluate the clinical relevance of the presurgical systemic inflammation response index (SIRI) in individuals undergoing radical cystectomy (RC). METHODS: In this retrospective study, 228 were categorized into 2 cohorts depending on their SIRI levels using the best cut-off determined by the Youden Index. The association between SIRI and lymph node metastasis (N), advanced pT stage (pT3/pT4), and loco-regional extended state were analyzed at the time of surgery. Multivariate Cox regression analysis was performed to evaluate the impact of SIRI on time to relapse, tumor-specific survival, and survival rates. The additional medical advantage was evaluated through decision curve analysis (DCA). RESULTS: High and low SIRI group was obtained using the best cut-off value (1.71×10(9)/l). On multivariate logistic regression analysis, elevated SIRI was significantly associated with advanced pT stage (P = 0.003) and loco-regional extended state (P = 0.003). On multivariable Cox regression models based on presurgical clinicopathological factors, an augmented SIRI was linked to poorer relapse-free survival (RFS) (P = 0.035), with the improvement of the concordance index just for RFS. In DCAs, incorporating SIRI yielded results equal to or better than those of the model without SIRI for all outcomes models. It demonstrated improvements in net benefit at probability thresholds up to 50% for the model adjusted with preoperative factors for RFS and for postoperative factors in CSS and OS. CONCLUSIONS: SIRI is an innovative prognostic indicator and a potential biomarker that can enhance conventional medical pathological evaluation and improve the personalization of clinical treatment strategies for bladder cancer patients following RC.	bladder
Outpatient Transurethral Resections of Bladder Tumors: Insights from the Largest Cohort to Date.	INTRODUCTION: Outpatient transurethral resection of bladder tumors (TURBT) is not widespread, involving only 5% of patients. Our aim was to assess the feasibility of TURBT in an outpatient setting and to evaluate factors possibly associated with conversion to inpatient care. METHODS: All consecutive outpatient-TURBT performed between January 2016 and December 2022 in one academic center was retrospectively analyzed. Outpatient success was defined as the absence of conversion to conventional hospitalization as well as the absence of unscheduled care within 30 postoperative days. The quality of the resection was assessed by the presence of detrusor muscle in the surgical specimen. RESULTS: A total of 500 consecutive outpatient-TURBT were included in 376 patients. Outpatient-TURBT was performed for primary tumor diagnosis in 187 (37%) cases, second look in 66 (13%) cases and tumor relapse in 216 (43%) cases. Muscle was present in 86% of cases. Perioperative inpatient conversions occurred in 40 cases (8%). Once converted, patients stayed a median of 2 days IQR (1;3). Seventy-seven post-TURBT unscheduled care were observed (15%) with 40 emergency room visits (8%) and/or 22 rehospitalizations (4%), occurring on a median postoperative day 3 IQR (1; 4). Overall complication rate was 11% (51 cases of grade 1 and 2 complications [10%] and 6 cases of grade 3 complications [1%]). Multivariate predictors of outpatient-TURBT failure were specimen weight ≥1 g (OR = 4.35, 95% CI: 1.60-13.3, p = 0.007), surgery duration (OR = 1.03, 95% CI: 1.06-1.71), p = 0.002) and antiplatelet treatment (OR = 2.86, 95% CI: 0.864-9.17, p = 0.077). CONCLUSION: Outpatient TURBT appears to be acceptable with an 8% conversion rate, as well as safe, with an 11% complication rate. Quality of the resection was not affected by the outpatient setting. Tumor weight ≥1 g, surgery duration and absence of antiplatelet treatment were significant multivariate predictors of outpatient surgery failure.	bladder
New Treatment Options for Non-Muscle-Invasive Bladder Cancer.	Non-muscle-invasive bladder cancer (NMIBC) comprises 75% of newly diagnosed bladder cancer and poses significant clinical challenges because of high recurrence and progression rates. Despite the effectiveness of Bacillus Calmette-Guérin (BCG) therapy after transurethral resection of bladder tumor (TURBT), BCG fails nearly 40% of patients, requiring alternative treatments. Traditionally, radical cystectomy has been the standard for BCG-unresponsive disease, although it significantly affects quality of life. Recent advances have focused on bladder-preserving therapies that leverage immune checkpoint inhibitors, viral gene therapies, novel drug delivery systems, and targeted molecular agents. Emerging approaches such as TAR-200 and UGN-102 offer novel intravesical delivery systems that enhance therapeutic efficacy while minimizing systemic adverse effects. Viral therapies, including nadofaragene firadenovec and CG0070, deliver immune-activating and oncolytic agents directly to urothelial tumor cells. Additionally, immune checkpoint inhibitors such as pembrolizumab and durvalumab have demonstrated potential for systemic treatments in BCG-unresponsive NMIBC and may show even more promise in combinations. Ongoing trials are expected to provide crucial data on these therapies' efficacy, particularly in high-risk and intermediate-risk populations. For low-grade NMIBC, efforts are underway to de-escalate care through active surveillance and novel adjuvant therapies, reducing the need for repeated TURBT procedures. Together, these advancements highlight a promising shift toward personalized, bladder-preserving strategies that prioritize patient quality of life while addressing unmet needs in NMIBC management.	bladder
New biomarkers for diagnosis of bladder cancer: a bibliometric analysis.	BACKGROUND/OBJECTIVES: Bladder cancer is a multifactorial disease, ranking as the 10th most common cancer globally and the fourth most common cancer in men and the ninth in women in the Western world. This bibliometric analysis aims to identify and evaluate scientific literature addressing new biomarkers for bladder cancer diagnosis, as well as to identify the most prolific organizations, authors, journals, countries, and keywords within this research domain. METHODS: An electronic search was conducted using Elsevier's Scopus database. From a total of 940 retrieved papers (published between 2019 and 2024), 493 were selected. For data analysis and visualization, the titles of articles, year of publication, countries, authors, journals, articles, and keywords were analyzed using Microsoft Excel, VOSviewer, and Biblioshiny. RESULTS: China published the most papers (200 articles) and received the highest number of citations, followed by the USA. While some countries, such as Egypt and India, published exclusively Single Country Publications (SCPs), others demonstrated a higher level of international collaboration, with at least half of their publications being Multi-Country Publications (MCPs). Countries with higher rates of MCPs were Greece (66.6%), Italy (53.8%), Korea, and France (50%). The journals that produced the most publications and received the highest number of citations were Cancers, International Journal of Molecular Sciences, and Frontiers in Oncology, confirming their role in producing high-impact research. CONCLUSIONS: The consistent distribution of publications over the years considered indicates a sustained interest in this field.	bladder
Occupational health topics series on the effects of chemicals: epidemiological and toxicological risk assessments of ortho-toluidine for bladder cancer.	OBJECTIVES: Our aim was to report integrative evidence for the health risk assessment of ortho-toluidine (OT) in bladder cancer in a mini-review of the recent studies of humans, experimental animals, and OT skin permeability. METHODS: Bladder cancer cases were identified in workers in Japan who were occupationally exposed in 2014-2017 to aromatic amines, primarily to the human carcinogen OT. RESULTS: A key epidemiological study of 98 aromatic amine-exposed workers in Japan showed a clear OT exposure-response relationship with a standardized incidence ratio. A rat model experimental study also indicated that OT and acetoaceto-o-toluidine are potent bladder carcinogens. Multiple mechanisms of OT-related bladder cancer have been proposed: metabolic activation to reactive metabolites that bind DNA and proteins, mutagenicity, oxidative DNA damage, chromosomal damage, and cytotoxicity by OT. Recent comprehensive analyses of DNA adducts in rats identified a number of common oxidative DNA adducts, including 8-OHdG, in the rat urothelium and indicated that oxidative stress may play a crucial role in the development of urinary cancer caused by OT. The skin permeability of 6 aromatic amines (o-toluidine, aniline, p-toluidine, o-anisidine, 2,4-dimethylaniline, and o-chloroaniline) was examined with the use of a 3-dimensional (3D) reconstructed human skin model; ~70%-80% of the 6 aromatic amines had permeated through the 3D skin within 8 hours. Genotoxic potency testing in a human urothelial cell line using γ-H2AX, a marker of DNA damage, suggested that OT exhibited strong γ-H2AX generation. CONCLUSIONS: Prolonged dermal exposure to OT along with other genotoxic aromatic amines over many years may contribute to the development of bladder cancer.	bladder
Influence of best objective response to first-line treatment on survival outcomes in advanced urothelial carcinoma in the era of sequential therapy with enfortumab vedotin.	OBJECTIVE: This study evaluated whether first-line treatment affects survival outcomes in patients with advanced urothelial carcinoma undergoing sequential therapy with chemotherapy, immune checkpoint inhibitors, and enfortumab vedotin. METHODS: This multicenter retrospective study included 57 patients treated at Hiroshima University Hospital and its affiliated institutions between 2009 and 2024. Patients received chemotherapy as a first-line treatment (gemcitabine plus cisplatin or carboplatin), followed by second-line immune checkpoint inhibitors (pembrolizumab or avelumab) and third-line enfortumab vedotin. Assessed outcomes included overall survival and time to treatment failure. Cox regression analysis identified prognostic factors for overall survival. RESULTS: Over a median follow-up of 20.5 months, median overall survival was not reached after first-line treatment. Gemcitabine with cisplatin was selected in 31.6% of cases, while gemcitabine and carboplatin was chosen in 68.4% of cases as the first-line treatment; subsequently, 66.7% received pembrolizumab, and 33.3% received avelumab in the second-line treatment. Patients who achieved a complete or partial response with the first-line treatment had significantly longer overall survivals from both first-line and enfortumab vedotin initiation than those with stable or progressive disease. In cases that achieved complete or partial responses, avelumab was more frequently selected as a second-line therapy. However, in the first-line treatment, multivariate analysis identified only stable or progressive disease as a significant predictor of worse overall survival. CONCLUSION: The best response to first-line treatment predicted both overall survival from first-line initiation and outcomes following enfortumab vedotin treatment, underscoring its prognostic value in sequential therapy for patients with advanced urothelial carcinoma.	bladder